Strategic partnerships Enable Injections has actively pursued and announced strategic partnerships with Aptar Digital Health to develop a digital companion solution for the enFuse on-body system, signaling a clear opportunity to cross-sell digital health enablement and integration services to pharma and device partners.

Digital health expansion The company is expanding into digital companion solutions for enFuse, aligning with market demand for connected drug delivery and remote monitoring capabilities, which opens doors to healthcare IT vendors, digital health platforms, and payer-focused integrations.

Strong financing With a substantial funding history including a $30 million recent investment and a $215 million Series C in 2022, Enable Injections demonstrates accessible capital to scale manufacturing, R&D, and global regulatory activity, supporting enterprise-level procurement discussions.

Global approvals enFuse has received device marketing authorizations from multiple ex-U.S. regulators and combination product approvals in the U.S., indicating a growing installed base and regulatory credibility that can be leveraged to expand customers and harmonize cross-border supply.

Healthcare collaboration Recent SFDA authorization for EMPAVELI injector based on enFuse and partnerships with Sobi for Aspaveli in SobI territories highlight a track record of collaboration with specialty pharma and biopharma, offering a pathway to co-development or distribution deals with specialty products and niche indications.